Finasteride is an orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used for a surgical alternative to the treatment of benign prostatic hyperplasia (benign prostatic hyperplasia or BPH), characterized by enlargement of the prostate, to alleviate the symptoms and reduce the risk of acute urinary retention and surgery; It can be used to treat alopecia in males or to treat excessive hair growth in women.
Sterling holds Certificate of Suitability n. R0-CEP 2008-130-Rev 01 issued by Quality of Medicines & HealthCare (EDQM) on 28/05/2010.
US DMF was submitted to FDA on 06/07/2005 and the following number was assigned n. 18483.
Drug product containing Sterling’s Finasteride is commercialized in Europe and in the USA.